AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39549554 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose of spermidine, nicotinamide, PEA, and OEA supplements
Number of subjects: 5
Study 39549554 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of spermidine, nicotinamide, PEA, and OEA supplements
Number of subjects: 5
Study 39549554 — intervention group
Group type: COMPARATOR
Intervention: Control (wheat flour)
Number of subjects: 5
Study 39549554 — intervention group
Group type: EXPERIMENTAL
Intervention: All supplement doses combined
Number of subjects: 5
Study 39549678 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrectinib (≥600 mg once daily)
Number of subjects: 179
Study 39549678 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib (250 mg twice daily)
Number of subjects: 179
Study 39549719 — intervention group
Group type: EXPERIMENTAL
Intervention: Setmelanotide (subcutaneous, once daily for 52 weeks, starting at 0.5 mg with increments of 0.5 mg every 2 weeks)
Number of subjects: 12
Study 39549720 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC (cisplatin 75 mg/m²)
Number of subjects: 415
Study 39549720 — intervention group
Group type: COMPARATOR
Intervention: No HIPEC
Number of subjects: 415
Study 39549720 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC
Number of subjects: 415
Study 39550172 — intervention group
Group type: EXPERIMENTAL
Intervention: Glofit-GemOx
Number of subjects: 274
Study 39550172 — intervention group
Group type: COMPARATOR
Intervention: R-GemOx
Number of subjects: 274
Study 39550530 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-month meditation-based program
Number of subjects: 134
Study 39550530 — intervention group
Group type: COMPARATOR
Intervention: Active control group (non-native language training)
Number of subjects: 134
Study 39550530 — intervention group
Group type: COMPARATOR
Intervention: Passive control group (no intervention)
Number of subjects: 134
Study 39550532 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Habits in Pregnancy and Beyond (HHIPBe) intervention
Number of subjects: 0
Study 39550532 — intervention group
Group type: COMPARATOR
Intervention: Ten Top Tips for a Healthy Weight (10TT)
Number of subjects: 0
Study 39550717 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviorally informed, electronically delivered, letter-based nudges
Number of subjects: 59458
Study 39550717 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviorally informed, electronically delivered, letter-based nudges (cardiovascular-gain frame letter)
Number of subjects: 59458
Study 39550716 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 6001
Study 39550716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6001
Study 39550720 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG plus partial cardiac denervation
Number of subjects: 430
Study 39550720 — intervention group
Group type: COMPARATOR
Intervention: CABG only (Control)
Number of subjects: 430
Study 39550721 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone (titrated to 20 mg or 40 mg)
Number of subjects: 6001
Study 39550721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6001
Study 39550721 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 6001
Study 39551007 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunct dextromethorphan (30 mg)
Number of subjects: 60
Study 39551007 — intervention group
Group type: COMPARATOR
Intervention: Adjunct placebo
Number of subjects: 60
Study 39551040 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (PAL) with letrozole (1L)
Number of subjects: 388
Study 39551040 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (PAL) in 1L
Number of subjects: 388
Study 39551040 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (PAL)
Number of subjects: 388
Study 39551040 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (PAL) with fulvestrant (first and later line)
Number of subjects: 388
Study 39551040 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (PAL) with anastrozole or exemestane (1L) and letrozole (later line)
Number of subjects: 388
Study 39551057 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based screening and treatment for Chlamydia trachomatis and Neisseria gonorrhoeae (males and females) and Trichomonas vaginalis (females only) offered over 12 months.
Number of subjects: 6361
Study 39551057 — intervention group
Group type: COMPARATOR
Intervention: Existing health services (control group).
Number of subjects: 6361
Study 39551057 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based screening and treatment for Chlamydia trachomatis and Neisseria gonorrhoeae.
Number of subjects: 6361
Study 39551057 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based screening and treatment for Trichomonas vaginalis.
Number of subjects: 6361
Study 39551057 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based screening and treatment for Neisseria gonorrhoeae.
Number of subjects: 6361
Study 39551062 — intervention group
Group type: EXPERIMENTAL
Intervention: MDA with dihydroartemisinin-piperaquine and ivermectin (300 μg/kg per day)
Number of subjects: 25882
Study 39551062 — intervention group
Group type: COMPARATOR
Intervention: MDA with dihydroartemisinin-piperaquine and placebo
Number of subjects: 25882
Study 39551064 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg starting 2 weeks before radiotherapy then every 4 weeks starting week 2 of radiotherapy (seven cycles)
Number of subjects: 190
Study 39551064 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab 400 mg/m2
Number of subjects: 190
Study 39551064 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 190
Study 39551064 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab
Number of subjects: 190
Study 39551093 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher sCD14 concentrations
Number of subjects: 240
Study 39551093 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher I-FABP concentrations
Number of subjects: 240
Study 39551093 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher alpha-1-acid glycoprotein concentrations
Number of subjects: 240
Study 39551132 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban, 2.5 mg twice daily for three months
Number of subjects: 186
Study 39551132 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 186
Study 39551147 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced HIV prevention intervention with accommodation strategies
Number of subjects: 50
Study 39551147 — intervention group
Group type: COMPARATOR
Intervention: HIV prevention intervention as treatment per usual (active control)
Number of subjects: 50
Study 39551147 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly PrEP adherence assessments
Number of subjects: 50
Study 39551147 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptability ratings of intervention content and accommodation strategies
Number of subjects: 50
Study 39551147 — intervention group
Group type: EXPERIMENTAL
Intervention: Feasibility measures via participant recruitment and retention
Number of subjects: 50
Study 39551167 — intervention group
Group type: EXPERIMENTAL
Intervention: mAFP (Impella CP) plus standard care
Number of subjects: 355
Study 39551167 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 355
Study 39551356 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary dietary fibers (total dietary fiber - complementary foods (g))
Number of subjects: 68
Study 39551356 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 68
Study 39551469 — intervention group
Group type: EXPERIMENTAL
Intervention: Deulorlatinib 60 mg once per day (recommended phase 2 dose)
Number of subjects: 198
Study 39551470 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 0
Study 39551470 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation immunotherapy
Number of subjects: 0
Study 39551470 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 39551579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox proportional hazards model for survival time from index assessment in the derivation cohort (N≈140,000).
Number of subjects: 200000
Study 39551579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox proportional hazards model for survival time from index assessment in the validation cohort (N≈60,000).
Number of subjects: 200000
Study 39551590 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab-adbm (Cyltezo)
Number of subjects: 0
Study 39551590 — intervention group
Group type: COMPARATOR
Intervention: adalimumab RP (Humira)
Number of subjects: 0
Study 39551600 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI5395 (recombinant attenuated Newcastle disease virus) administered intravenously as six doses over 15-18 days
Number of subjects: 39
Study 39551600 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (anti-PD-L1 immune checkpoint inhibitor)
Number of subjects: 39
Study 39551608 — intervention group
Group type: EXPERIMENTAL
Intervention: Marathon runners
Number of subjects: 129
Study 39551608 — intervention group
Group type: COMPARATOR
Intervention: Patients with type 1 MI
Number of subjects: 129
Study 39551735 — intervention group
Group type: EXPERIMENTAL
Intervention: Three daily assessments of depressive symptoms across one menstrual cycle
Number of subjects: 77
Study 39551766 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Disease Management Test (CDMT) used by intervention PCPs.
Number of subjects: 333
Study 39551766 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group).
Number of subjects: 333
Study 39551791 — intervention group
Group type: EXPERIMENTAL
Intervention: HTNV DNA vaccine (2 mg/vaccination)
Number of subjects: 22
Study 39551791 — intervention group
Group type: EXPERIMENTAL
Intervention: PUUV DNA vaccine (2 mg/vaccination)
Number of subjects: 22
Study 39551791 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined HTNV/PUUV DNA vaccine (2 mg/vaccination of 1:1 mixture)
Number of subjects: 22
Study 39551791 — intervention group
Group type: EXPERIMENTAL
Intervention: HTNV DNA vaccine
Number of subjects: 22
Study 39551791 — intervention group
Group type: EXPERIMENTAL
Intervention: PUUV DNA vaccine
Number of subjects: 22
Study 39551821 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative surgical approach
Number of subjects: 1
Study 39551891 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Number of subjects: 731
Study 39552082 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Patient Simulation (VPS)
Number of subjects: 40
Study 39552082 — intervention group
Group type: COMPARATOR
Intervention: In-Person Simulation (IPS)
Number of subjects: 40
Study 39552153 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 23
Study 39552427 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39552592 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Channel Blockers
Number of subjects: 0
Study 39552592 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 39552638 — intervention group
Group type: EXPERIMENTAL
Intervention: 2LM niraparib monotherapy
Number of subjects: 199
Study 39552638 — intervention group
Group type: COMPARATOR
Intervention: Active surveillance (AS)
Number of subjects: 199
Study 39552682 — intervention group
Group type: EXPERIMENTAL
Intervention: Total elbow arthroplasty (TEA)
Number of subjects: 13
Study 39552682 — intervention group
Group type: COMPARATOR
Intervention: Distal humeral hemiarthroplasty (HA)
Number of subjects: 13
Study 39552943 — intervention group
Group type: EXPERIMENTAL
Intervention: Support Group Leader EDucation Program (13-session training via videoconference)
Number of subjects: 148
Study 39552943 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 148
Study 39553451 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media use
Number of subjects: 4000
Study 39553451 — intervention group
Group type: EXPERIMENTAL
Intervention: Television viewing
Number of subjects: 4000
Study 39553451 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen time (general)
Number of subjects: 4000
Study 39553451 — intervention group
Group type: EXPERIMENTAL
Intervention: Hostile thoughts
Number of subjects: 4000
Study 39553845 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized risk prediction system for mortality
Number of subjects: 965
Study 39553845 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized risk prediction system for rehospitalization for heart failure
Number of subjects: 965
Study 39553900 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAO combined with catheter ablation
Number of subjects: 3096
Study 39553900 — intervention group
Group type: COMPARATOR
Intervention: LAAO only
Number of subjects: 3096
Study 39553907 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography-derived fractional flow reserve (FFR)
Number of subjects: 245
Study 39553907 — intervention group
Group type: EXPERIMENTAL
Intervention: High FFR
Number of subjects: 245
Study 39553909 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine integrated care
Number of subjects: 1039
Study 39553909 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 1039
Study 39554793 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 554
Study 39554834 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus brief healthy diet and exercise education (MET+LIFE)
Number of subjects: 1637
Study 39554834 — intervention group
Group type: COMPARATOR
Intervention: LIFE alone
Number of subjects: 1637
Study 39555240 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitor therapy
Number of subjects: 0
Study 39555240 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (not specified)
Number of subjects: 0
Study 39555321 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoPrognosis machine learning model
Number of subjects: 960
Study 39555321 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest (RF)
Number of subjects: 960
Study 39555321 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient Boosting (GB)
Number of subjects: 960
Study 39555321 — intervention group
Group type: EXPERIMENTAL
Intervention: XGBoost
Number of subjects: 960
Study 39555321 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic Regression (LR)
Number of subjects: 960
Study 39555388 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction algorithm for exacerbations in COPD patients
Number of subjects: 111
Study 39555632 — intervention group
Group type: COMPARATOR
Intervention: Psychostimulants
Number of subjects: 136
Study 39555642 — intervention group
Group type: EXPERIMENTAL
Intervention: Laughter yoga (twice a week for 35-40 minutes, six sessions total)
Number of subjects: 60
Study 39555642 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 39555800 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACYW-TT booster vaccination
Number of subjects: 0
Study 39555800 — intervention group
Group type: COMPARATOR
Intervention: MPSV4 priming
Number of subjects: 0
Study 39555800 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACYW-TT and MPSV4
Number of subjects: 0
Study 39555814 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 7062
Study 39555814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7062
Study 39555818 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral infigratinib at 0.25 mg/kg for 18 months (cohort 5)
Number of subjects: 72
Study 39555820 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 416
Study 39555820 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy (sotalol or amiodarone)
Number of subjects: 416
Study 39555823 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 7062
Study 39555823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7062
Study 39555822 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure
Number of subjects: 1600
Study 39555822 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulation
Number of subjects: 1600
Study 39555826 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide (up to 15 mg subcutaneously once per week)
Number of subjects: 731
Study 39555826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 731
Study 39555826 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Number of subjects: 731
Study 39555827 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment targeting systolic blood pressure <120 mm Hg
Number of subjects: 12821
Study 39555827 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment targeting systolic blood pressure <140 mm Hg
Number of subjects: 12821
Study 39555827 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 12821
Study 39555827 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 12821
Study 39555828 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexiguran ziclumeran (nex-z)
Number of subjects: 36
Study 39556016 — intervention group
Group type: EXPERIMENTAL
Intervention: RP-A501 infusion with transient immunomodulatory regimen (prednisone, tacrolimus or sirolimus, and rituximab)
Number of subjects: 7
Study 39556016 — intervention group
Group type: EXPERIMENTAL
Intervention: RP-A501 infusion
Number of subjects: 7
Study 39556124 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 108
Study 39556192 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)
Number of subjects: 2622
Study 39556192 — intervention group
Group type: COMPARATOR
Intervention: Dolutegravir (DTG) + 2 NRTIs
Number of subjects: 2622
Study 39556238 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up Online (FCU-O)
Number of subjects: 374
Study 39556238 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 374
Study 39556379 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI plus EIVOM and linear ablation
Number of subjects: 498
Study 39556379 — intervention group
Group type: COMPARATOR
Intervention: PVI alone
Number of subjects: 498
Study 39556389 — intervention group
Group type: EXPERIMENTAL
Intervention: gantenerumab
Number of subjects: 1939
Study 39556389 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1939
Study 39556397 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE), 50 hours over 2 weeks
Number of subjects: 46
Study 39556397 — intervention group
Group type: COMPARATOR
Intervention: Usual motor activities (Control)
Number of subjects: 46
Study 39556768 — intervention group
Group type: EXPERIMENTAL
Intervention: Muvalaplin 10 mg/d
Number of subjects: 233
Study 39556768 — intervention group
Group type: EXPERIMENTAL
Intervention: Muvalaplin 60 mg/d
Number of subjects: 233
Study 39556768 — intervention group
Group type: EXPERIMENTAL
Intervention: Muvalaplin 240 mg/d
Number of subjects: 233
Study 39556768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 39556772 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin infusion (1 pmol/kg/min)
Number of subjects: 25
Study 39556772 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 25
Study 39556810 — intervention group
Group type: EXPERIMENTAL
Intervention: Live With Wearable Monitoring Device program with ongoing professional and peer support (1 home visit and biweekly communication via WhatsApp)
Number of subjects: 76
Study 39556810 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 76
Study 39556824 — intervention group
Group type: EXPERIMENTAL
Intervention: Sling wear (intervention group)
Number of subjects: 0
Study 39556824 — intervention group
Group type: COMPARATOR
Intervention: Not specified (control group)
Number of subjects: 0
Study 39556824 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified (intervention)
Number of subjects: 0
Study 39557058 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus ramucirumab (switch maintenance group)
Number of subjects: 280
Study 39557058 — intervention group
Group type: COMPARATOR
Intervention: Continuation of FOLFOX or CAPOX (control group)
Number of subjects: 280
Study 39557109 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban + placebo
Number of subjects: 4614
Study 39557109 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban + aspirin
Number of subjects: 4614
Study 39557109 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin + placebo
Number of subjects: 4614
Study 39557109 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin + aspirin
Number of subjects: 4614
Study 39557109 — intervention group
Group type: COMPARATOR
Intervention: Apixaban vs. Warfarin
Number of subjects: 4614
Study 39557109 — intervention group
Group type: COMPARATOR
Intervention: Aspirin vs. Placebo
Number of subjects: 4614
Study 39557398 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin levels
Number of subjects: 164
Study 39557398 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age, hyperlipidemia, and higher leptin levels
Number of subjects: 164
Study 39557398 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcium (CAC) scores
Number of subjects: 164
Study 39557487 — intervention group
Group type: EXPERIMENTAL
Intervention: Fezolinetant 45 mg once daily for 24 weeks
Number of subjects: 453
Study 39557487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 453
Study 39557547 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent behavioural economic nudge intervention
Number of subjects: 0
Study 39557547 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 39557549 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth treatment (audio-only mobile phone)
Number of subjects: 2162
Study 39557549 — intervention group
Group type: COMPARATOR
Intervention: In-person treatment
Number of subjects: 2162
Study 39557557 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of acetylsalicylic acid daily (LDA)
Number of subjects: 250